Literature DB >> 18515154

Surgery for temporal lobe epilepsy after cerebral malaria.

O E M G Schijns1, V Visser-Vandewalle, E M P Lemmens, A Janssen, G Hoogland.   

Abstract

The most common indication for epilepsy surgery is temporal lobe epilepsy (TLE) which usually is divided into two categories, mesial and lateral TLE. The commonest pathology underlying mesial temporal lobe epilepsy (MTLE) is mesial temporal sclerosis (MTS); we report on a 50-year-old male patient, who contracted cerebral malaria and developed MTLE shortly thereafter. Magnetic resonance imaging (MRI) showed MTS. Surgical treatment was an anteromedial temporal lobe resection with amygdalohippocampectomy. The patient is seizure free, 36 months after surgical treatment. This is the first report describing MTLE-onset subsequent to cerebral malaria and discussing the potential pathophysiological relationship between cerebral malaria and MTS.

Entities:  

Mesh:

Year:  2008        PMID: 18515154     DOI: 10.1016/j.seizure.2008.04.006

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

1.  Impaired everyday memory associated with encephalopathy of severe malaria: the role of seizures and hippocampal damage.

Authors:  Michael Kihara; Julie A Carter; Penny A Holding; Faraneh Vargha-Khadem; Rod C Scott; Richard Idro; Greg W Fegan; Michelle de Haan; Brian G R Neville; Charles R J C Newton
Journal:  Malar J       Date:  2009-12-01       Impact factor: 2.979

2.  Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Authors:  Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

3.  Seizure freedom following surgery for multi-focal epilepsy due to cerebral malaria.

Authors:  Peraya Piromruen; Chusak Limotai
Journal:  Epilepsy Behav Case Rep       Date:  2017-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.